<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00537121</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000564857</org_study_id>
    <secondary_id>RPCI-I-78806</secondary_id>
    <nct_id>NCT00537121</nct_id>
  </id_info>
  <brief_title>Vorinostat, Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Upper Gastrointestinal Cancer</brief_title>
  <official_title>Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (VORINOSTAT)] With Irinotecan, 5-Fluorouracil (5-FU) and Leucovorin (FOLFIRI) for Advanced Upper Gastrointestinal Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vorinostat may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth. Drugs used in chemotherapy, such as irinotecan, fluorouracil, and&#xD;
      leucovorin, work in different ways to stop the growth of tumor cells, either by killing the&#xD;
      cells or by stopping them from dividing. Giving vorinostat together with combination&#xD;
      chemotherapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of vorinostat when&#xD;
      given together with irinotecan, fluorouracil, and leucovorin in treating patients with&#xD;
      advanced upper gastrointestinal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose (MTD) and recommended phase II dose (RPTD) of&#xD;
           vorinostat (SAHA) when administered continuously with standard doses of irinotecan&#xD;
           hydrochloride, fluorouracil, and leucovorin calcium (FOLFIRI) in patients with advanced&#xD;
           upper gastrointestinal cancer.&#xD;
&#xD;
        -  Determine the MTD and RPTD of SAHA when administered intermittently with standard doses&#xD;
           of FOLFIRI in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Describe the toxicity of the SAHA and FOLFIRI combination.&#xD;
&#xD;
        -  Explore the effects of SAHA and FOLFIRI combination on TGF-β expression.&#xD;
&#xD;
        -  Explore the alteration of survivin expression by the SAHA and FOLFIRI combination.&#xD;
&#xD;
        -  Describe the effect of FOLFIRI on the pharmacokinetics of SAHA.&#xD;
&#xD;
        -  Describe the effect of SAHA on the pharmacokinetics of irinotecan.&#xD;
&#xD;
        -  Describe the response rate, progression-free survival, and overall survival of patients&#xD;
           treated with this regimen.&#xD;
&#xD;
      OUTLINE: Patients receive irinotecan hydrochloride IV over 90 minutes and leucovorin calcium&#xD;
      IV over 2 hours on day 1 and fluorouracil IV continuously over 46 hours on days 1 and 2&#xD;
      (FOLFIRI). Patients also receive oral vorinostat (SAHA) according to 1 of the following&#xD;
      dosing regimens outlined below, depending upon time of study entry:&#xD;
&#xD;
        -  Determination of maximum tolerated dose (MTD) for continuous SAHA dosing: Patients&#xD;
           receive SAHA once daily on days 2-14 of course 1 and then on days 1-14 of all subsequent&#xD;
           courses.&#xD;
&#xD;
        -  Evaluation of SAHA pharmacokinetics at MTD for continuous dose SAHA: Patients receive&#xD;
           SAHA on day -7 (before beginning course 1) and then once daily on days 1-14 at the MTD.&#xD;
&#xD;
        -  Determination of MTD for intermittent SAHA: Patients receive SAHA once daily on days 1-7&#xD;
           at the MTD determined for continuous SAHA dosing. Patients receive escalating doses of&#xD;
           SAHA until the MTD of intermittent SAHA is determined.&#xD;
&#xD;
      Treatment with FOLFIRI and vorinostat repeats every 2 weeks for 24 courses in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      Some patients undergo tumor tissue and blood sample collection periodically for&#xD;
      pharmacokinetic and correlative studies. Tumor tissue samples are assessed for TGF-β&#xD;
      expression by immunohistochemical methods and by reverse transcriptase-polymerase chain&#xD;
      reaction for mRNA expression. Immunohistochemistry and immunoenzymatic techniques are&#xD;
      performed to study survivin expression before beginning treatment and after completion of&#xD;
      course 1. Pharmacokinetic studies for irinotecan, SN38, and SN38G are obtained on days 1&#xD;
      (before SAHA) and 15 (after SAHA). Blood is also collected for analysis of UGT1A1&#xD;
      polymorphism. Other patients undergo blood collection on days -7 (before FOLFIRI) and 2 (with&#xD;
      FOLFIRI) for vorinostat Pharmacokinetic studies. Samples are analyzed by liquid&#xD;
      chromatography-mass spectrometry.&#xD;
&#xD;
      After completion of study treatment, patients are followed for 4 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of vorinostat (SAHA) when administered continuously and intermittently with standard doses of irinotecan hydrochloride, fluorouracil, and leucovorin calcium (FOLFIRI)</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended phase II dose (RPTD) of SAHA when administered continuously and intermittently with standard doses of FOLFIRI</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity of the SAHA and FOLFIRI combination</measure>
    <time_frame>Baseline and after 2 weeks of Treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of SAHA and FOLFIRI combination on TGF-β signaling and survivin expression</measure>
    <time_frame>Every 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Every 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Every 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Every 3 months for 5 years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">23</enrollment>
  <condition>Esophageal Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Liver Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <description>Given IV</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
    <description>Given IV</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
    <description>Given IV</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vorinostat</intervention_name>
    <description>Taken Orally</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative Study</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed upper gastrointestinal tract cancer, including any of the&#xD;
             following:&#xD;
&#xD;
               -  Esophageal cancer (adenocarcinoma or squamous cell carcinoma)&#xD;
&#xD;
               -  Gastric cancer (adenocarcinoma or squamous cell carcinoma)&#xD;
&#xD;
               -  Hepatocellular carcinoma&#xD;
&#xD;
          -  Locally advanced, inoperable disease or metastatic disease&#xD;
&#xD;
          -  No uncontrolled brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status (PS) 0-1 (Karnofsky PS ≥ 70%)&#xD;
&#xD;
          -  Life expectancy &gt; 12 weeks&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mcL&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mcL&#xD;
&#xD;
          -  Leukocytes ≥ 3,000/mcL&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times upper limit of normal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Able to understand and willing to sign a written informed consent document&#xD;
&#xD;
          -  No history of allergic reactions attributed to compounds of similar chemical or&#xD;
             biologic composition to vorinostat (SAHA) or other agents used in the study&#xD;
&#xD;
          -  No uncontrolled intercurrent illness including, but not limited to, any of the&#xD;
             following:&#xD;
&#xD;
               -  Ongoing or active infection&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Uncontrolled hypertension&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Cardiac arrhythmia&#xD;
&#xD;
               -  Psychiatric illness/social situations that would limit compliance with study&#xD;
                  requirements&#xD;
&#xD;
          -  No coagulopathy or bleeding disorder&#xD;
&#xD;
          -  No known UGT1A1 polymorphism&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No more than 1 prior chemotherapy for metastatic disease&#xD;
&#xD;
          -  No prior histone deacetylase inhibitors&#xD;
&#xD;
          -  No concurrent prophylactic hematologic growth factors&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No concurrent valproic acid&#xD;
&#xD;
          -  No other concurrent investigational therapy&#xD;
&#xD;
          -  Concurrent therapeutic anticoagulation therapy is allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nikhil Khushalani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>September 27, 2007</study_first_submitted>
  <study_first_submitted_qc>September 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2007</study_first_posted>
  <last_update_submitted>June 26, 2013</last_update_submitted>
  <last_update_submitted_qc>June 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent gastric cancer</keyword>
  <keyword>stage IV gastric cancer</keyword>
  <keyword>recurrent esophageal cancer</keyword>
  <keyword>stage IV esophageal cancer</keyword>
  <keyword>adenocarcinoma of the esophagus</keyword>
  <keyword>adenocarcinoma of the stomach</keyword>
  <keyword>squamous cell carcinoma of the esophagus</keyword>
  <keyword>adult primary hepatocellular carcinoma</keyword>
  <keyword>stage III gastric cancer</keyword>
  <keyword>stage III esophageal cancer</keyword>
  <keyword>advanced adult primary liver cancer</keyword>
  <keyword>localized unresectable adult primary liver cancer</keyword>
  <keyword>recurrent adult primary liver cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Vorinostat</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

